Ryan Fukushima Sells 10,000 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. Following the sale, the chief executive officer directly owned 201,047 shares of the company’s stock, valued at approximately $12,062,820. The trade was a 4.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The stock was sold at an average price of $44.07, for a total value of $597,148.50.

Tempus AI Price Performance

NASDAQ TEM opened at $61.50 on Friday. The company has a market capitalization of $11.04 billion, a PE ratio of -35.76 and a beta of 3.46. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The business’s fifty day moving average is $51.12 and its 200 day moving average is $54.33. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The business had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Tempus AI’s revenue for the quarter was up 36.1% on a year-over-year basis. Sell-side analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Tempus AI

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CoreCap Advisors LLC grew its holdings in Tempus AI by 293.4% during the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company’s stock valued at $59,000 after buying an additional 760 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of Tempus AI by 1.3% during the 1st quarter. NewEdge Advisors LLC now owns 42,996 shares of the company’s stock worth $1,944,000 after acquiring an additional 536 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of Tempus AI during the 1st quarter worth approximately $1,130,000. Silverback Asset Management LLC boosted its position in shares of Tempus AI by 44.5% during the 1st quarter. Silverback Asset Management LLC now owns 35,700 shares of the company’s stock valued at $1,614,000 after acquiring an additional 11,000 shares during the last quarter. Finally, Vestor Capital LLC boosted its position in shares of Tempus AI by 338.2% during the 1st quarter. Vestor Capital LLC now owns 1,538 shares of the company’s stock valued at $70,000 after acquiring an additional 1,187 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on TEM shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. HC Wainwright dropped their price target on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Guggenheim reduced their price objective on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Finally, Needham & Company LLC restated a “buy” rating and set a $75.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $68.54.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.